BioTech Scout

Discover the most promising early-stage companies in life sciences, scouted by BioPharmaTrend. Follow company news and important business events.

back to Directory

Insilico Medicine

Insilico Medicine logo

Website
https://insilico.com/
Founded
2014
Patents
12
Publications
160

Technologies

AI Companies (Drug Discovery)

InSilico Medicine is a globally leading generative AI-driven biotech company in terms of AIDD pipeline progress providing end-to-end solutions. Founded in 2014 at the Emerging Technology Centers of Johns Hopkins University in Baltimore, Maryland, the company has a global presence in the U.S., Greater China, Canada, and the Middle East.

By leveraging the company’s rapidly evolving, proprietary Pharma.AI platform across biology, chemistry and clinical development, the company aims at a mission to accelerate drug discovery and development. Pharma.AI platform consisting of Biology42, Chemistry42 and Medicine42, which are designed to be integrated across the drug discovery and development process to efficiently identify novel drug targets, design de novo molecules against both novel and known targets and optimize clinical development.

reinforcement learning drug development Generative adversarial networks biomarker development longevity aging

Interviews

Posts Mentioning This Company

Building Momentum for Global AI-driven Longevity Transformation

  
Today, Insilico Medicine, a leading player in artificial intelligence (AI)-driven drug discovery and longevity research, tops up its recent $60 million Series D with additional $35 million from Prosperity7 Ventures, a global VC fund by Saudi Arabia’s giant Aramco. This investment by Aramco is yet another step within Saudi Arabia’s …

11 Biopharma Trends to Watch in 2024

  
2023 has marked a remarkable year of technological advancements in drug discovery and biotechnology. Ironically, the elation from a kaleidoscope of technological and scientific advances is in stark contrast with the overall industry’s economic performance—it was also a rough year for biopharma overall. There are signs that 2024 might be better …

9 Innovative Life Sciences Companies to Watch in 2024

  
The biotech and pharmaceutical industries are entering 2024 amid a wave of innovation and technological advancement.  The biopharma field is increasingly influenced by the advent of cutting-edge technologies such as artificial intelligence (AI), organ-on-a-chip systems, and gene editing therapies promising more personalized and precise treatments for a variety of conditions.
Top AI Drug Discovery Companies Transforming the Pharma Industry

Tech-First Companies Take the Lead in AI Drug Discovery

  
In recent news, Recursion (NASDAQ: RXRX), a prominent clinical stage TechBio firm, has announced the signing of agreements to acquire Cyclica and Valence, two companies with expertise in AI-enabled drug discovery. These acquisitions strengthen Recursion's position in computational chemistry, machine learning, and artificial intelligence, enhancing its technology-enabled drug discovery capabilities …

2022 in Retrospect: 10 Breakthrough Technologies in Drug Discovery

  
Reflecting on 2022, let’s review several breakthrough technologies that are shaping the future of biology research and drug discovery. I have prepared this list based on a review of recent articles published on BiopharmaTrend -- by myself and by numerous guest authors.

15 Biopharma Research Trends to Watch in 2022

  
Table of contents:    mRNA vaccines and RNA therapies  Epitranscriptomics Targeting RNA with small molecules Deep learning and big data in drug discovery Neoantigens Theranostics  Exosomes Synthetic Biology 3D Bioprinting Antibiotics “anti-trend” (and hope?) Nanotechnologies in Drug Delivery Gene Editing (CRISPR-Cas9) Aging research  Microbiome  Protein Degraders   Discoveries made in …

A Race For Better 3CL Inhibitors to Cure COVID-19: Copies vs. Innovators

  
Disclaimer: This post is not medical advice and is for informational purposes only. All the information contained here is related to research and development and is not intended for clinical use. Never attempt to take any medications without consulting with your medical doctor.    The global COVID-19 pandemic is far …

9 Companies Using Artificial Intelligence to Fight Infectious Diseases

  
Development of a novel drug is a tedious process that requires immense investments of resources and time - on average, it takes at least ten years and $ 2.6 B for a new medicine to complete the journey from initial discovery to the marketplace. And then patents give pharmaceutical companies …

AI Helps Discover Potential First-in-class Molecule for Immuno-oncology for Fosun Pharma

  
The global artificial intelligence (AI) leader Insilico Medicine announced its first milestone in cancer immunotherapy for their external collaboration with Fosun Pharmaceuticals (600196.SH, 02196.HK), an international healthcare group in China. In under 40 days since the collaboration announcement, companies nominated the first preclinical drug candidate ISM004-1057D, a potential first-in-class small …

Pharmaceutical AI in 2021: Key Developments So Far

  
Table of Contents:   Introduction Artificial intelligence (AI) in drug discovery yields breakthroughs The abundance of venture capital, major funding rounds IPOs of AI Pharma Companies in 2021 New AI-driven biotech startups founded in 2020 Notable AI-focused collaborations involving “big pharma” players AI adoption by the contract research organizations (CROs)  …
CROs Tap Into AI To Increase Value Proposition

Contract Research Organizations Tap Into AI To Increase Value Proposition

  
A few decades ago, pharmaceutical giants did most of the discovery work in-house, along with every other work necessary to get a drug or medical device to market. Nowadays, nearly any type of R&D or regulatory filing work that a drug maker or a medical-device producer needs to do -- …
The Increasing Potential of VR in Drug Design

The Increasing Potential of Virtual Reality in Drug Design

  
Using virtual reality (VR) for manipulating 3D models of molecules in the context of drug design is an emerging technological opportunity, which increasingly grabs attention among scientists at biotech startups, and larger pharmaceutical organizations. 
Pharma Companies Race To Tackle Wuhan Coronavirus Outbreak

How Pharma Reacts To Wuhan Coronavirus Outbreak

  
UPDATE April 04. 2020. The number of confirmed cases of COVID19 approaches 1M globally. Since too many drug repurposing programs and vaccine development projects have been urgently initiated, we decided to summarize them in a separate post: A Running List Of COVID-19 Treatments And Vaccines In Development With this, we …
Artificial Intelligence Yields Early Results in Drug Discovery

Artificial Intelligence Yields Early Results in Drug Discovery

  
A historically significant milestone has just been reached by Oxford, UK-based Exscientia, which used its artificial intelligence (AI)-based drug discovery platform Centaur Chemist™ to deliver the first drug candidate in the framework of their multiyear collaboration with GSK. This AI-derived small molecule is a highly potent in vivo active substance …
Pharma and Healthcare AI Vendors Join Forces To Accelerate Progress In Drug Discovery

Pharma and Healthcare AI Vendors Join Forces To Accelerate Progress In Drug Discovery

  
Today Basel is crowded with some of the top business and research leaders representing a young and rapidly growing industry of artificial intelligence (AI) in healthcare and pharmaceutical research. They come together to announce mission and launch activities of a global Alliance for Artificial Intelligence in Healthcare (AAIH), which is …
2018 Brings A Surge Of Activity In The “AI For Drug Discovery” Space

2018 Brings A Surge Of Activity In The “AI For Drug Discovery” Space

  
(Last updated: 15.03.2018) The idea of using artificial intelligence (AI) to accelerate drug discovery process and boost a success rate of pharmaceutical research programs has inspired a notable amount of activity over the last several years with a considerable number of initiated research collaborations between AI-driven R&D vendors and top …